Daily biotech dealflow + market tape in 5 minutes — for VC, BD&L, and public biotech investors.
Newsletter
Sep 10, 2026
•
5 min read
Bayer takes first-line HER2 lung, Solstice debuts big, and WCLC is two days out.
Sep 9, 2026
A survival win, a 10% drawdown, and an oral HAE drug at 83%.
Sep 8, 2026
4 min read
Novo scraps two more ziltivekimab trials, and FDA approves a drug off a blood test.
Sep 4, 2026
An ultra-rare approval, a 74% response rate, and a licence signed before Phase 1.
Sep 3, 2026
A clean Phase 3 miss, an FDA warning shot, and $3.22B for a better needle.
Sep 1, 2026
Class-wide safety scare, a 26-name pricing club, and ARCH goes shopping for $3B.
Aug 31, 2026
ESC hands out a split verdict; Takeda's $275M cheque clears on the way.
Aug 28, 2026
Roivant finally has something to sell, and Genentech pays up for the payload after next.
Aug 27, 2026
Revolution's review clock ran fast, Biohaven's ran out of patience at $795M.
